Pulmonary Arterial Hypertension

Physician Registration

Interested in Conducting a
Clinical Research Trial?

Click Here for
Physician Partner Registration

One Year Study – Study No. AC-063A406

One Year Study – Study No. AC-063A406

A multicenter, retrospective study of patients with pulmonary arterial hypertension receiving inhaled iloprost for ≥ year

AMBITION: A Randomised, Multicenter Study of First-Line

A randomised multicenter study comparing the effect on time to

clinical failure of initial combination therapy (ambrisentan and

tadalafil) and initial monotherapy (ambrisentan or tadalafil) in

subjects with pulmonary arterial hypertension.

Ventavis® Registry Protocol (RESPIRE)

The Ventavis® (iloprost) Registry is a multicenter, observational, U.S.-based study that longitudinally follows patients with pulmonary arterial hypertension (PAH) who have been receiving therapy with Ventavis® for at least 3 months. Patients diagnosed with WHO Group I PAH who are on a stable regimen of commercial Ventavis® will be followed for a maximum of 2 years from the time of enrollment. Data will be collected via patient interview and review of the medical record. Quarterly data collection will include capture of medications and Ventavis® adherence data.

Iloprost Power Disc-15 in Pulmonary Arterial Hypertension (INHALE-15)

A Phase IIIb, Multicenter, Open-Label Study of Patients With Pulmonary Arterial Hypertension Treated With Iloprost(Inhalation)Evaluating Safety and Inhalation Times When Converting From Power Disc-6 to Power Disc-15 With the I-Neb® AAD®Adult Patients